{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:56:57Z","timestamp":1790888217811,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2006,4,3]],"date-time":"2006-04-03T00:00:00Z","timestamp":1144022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The safety and efficacy of the interleukin\u20102 diphtheria toxin fusion protein (DAB<jats:sub>389<\/jats:sub>IL2; denileukin diftitox) directed against the IL\u20102 receptor (IL\u20102R) was tested in patients with recurrent or refractory chronic lymphocytic leukemia (CLL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Denileukin diftitox was administered as 60\u2010minute intravenous infusions for 5 days every 21 days at a dose of 18 \u03bcg\/kg per day for up to 8 cycles. In total, 28 patients were treated in 2 multiinstitutional studies with similar eligibility criteria and treatment protocols. Twenty\u2010two patients receive \u22652 cycles of denileukin diftitox and were evaluable for response.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twelve of 22 patients achieved reductions of peripheral CLL cells, with 5 of 12 patients achieving &gt;80% reductions. Six of 22 patients achieved reductions in the size of lymph node on examination and computed tomography scans, and all 6 of those patients met the criteria for a partial or complete response that lasted \u22652 months. Bone marrow biopsies before and after treatment confirmed a complete remission that lasted for 1 year in 1 patient. Overall, denileukin diftitox produced complete remission in 1 of 22 patients (4%) and partial remission in 5 of 22 patients (23%) for a total remission rate of 27%. Progression\u2010free intervals in the responders were 2 months in 2 patients and 4 months, 6 months, 7 months, and 12 months in 1 patient each. Toxicities were moderate. No infections associated with immunosuppression were seen. There was no significant correlation of response or toxicities with the numbers of denileukin diftitox cycles received or with CD25 levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Follow\u2010up studies will be required to identify predictors of response that may improve the response rate to denileukin diftitox in patients with CLL. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21851","type":"journal-article","created":{"date-parts":[[2006,4,3]],"date-time":"2006-04-03T17:46:25Z","timestamp":1144086385000},"page":"2158-2164","source":"Crossref","is-referenced-by-count":40,"title":["Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia"],"prefix":"10.1002","volume":"106","author":[{"given":"Arthur E.","family":"Frankel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Surendranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Ganjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2004.00489.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.531"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0796"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2276"},{"key":"e_1_2_5_7_2","first-page":"100a","article-title":"Phase 3 randomized trial of fludarabine\/cyclophos\u2010phamide chemotherapy with or without oblimersen sodium (Bcl\u20102 antisense; Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"104","author":"Rai K","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.02.008"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"11885","DOI":"10.1016\/S0021-9258(19)38482-0","article-title":"Structure\/function analysis of interleukin\u20102\u2010toxin (DAB486\u2010IL\u20102). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells","volume":"265","author":"Williams DP","year":"1990","journal-title":"J Biol Chem."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(94)00085-9"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2004.06.010"},{"key":"e_1_2_5_12_2","first-page":"2590","article-title":"Interleukin 2 (IL\u20102) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL\u20102 in cultured hematopoietic cells","volume":"56","author":"Re GG","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_5_13_2","first-page":"399","article-title":"Phase I trial of a ligand fusion\u2010protein (DAB389IL\u20102) in lymphomas expressing the receptor for interleukin\u20102","volume":"91","author":"LeMaistre CF","year":"1998","journal-title":"Blood."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2001.n.005"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.071"},{"key":"e_1_2_5_17_2","first-page":"1571","article-title":"Characterization of interleukin 2 receptors on B\u2010cell chronic lymphocytic leukemia cells","volume":"8","author":"Tsilivakos V","year":"1994","journal-title":"Leukemia."},{"key":"e_1_2_5_18_2","first-page":"3555","article-title":"A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine\u2010refractory chronic lymphocytic leukemia","volume":"9","author":"Frankel AE","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1158\/1078-0432.3572.10.10","article-title":"Confirmation of the activity of the interleukin\u20102 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia including cases with chromosome 17p deletion and without detectable CD25 expression","volume":"10","author":"Morgan SJ","year":"2004","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.0680"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0642"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425887"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21851","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:25:29Z","timestamp":1760289929000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,5,15]]}},"alternative-id":["10.1002\/cncr.21851"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21851","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}